

RealRate

PHARMACEUTICAL 2022

Vaxxinity Inc. Rank 394 of 475







PHARMACEUTICAL 2022

Vaxxinity Inc. Rank 394 of 475



The relative strengths and weaknesses of Vaxxinity Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vaxxinity Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Vaxxinity Inc. is the variable Net Income, reducing the Economic Capital Ratio by 250% points.

The company's Economic Capital Ratio, given in the ranking table, is -406%, being 129% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	154,129
Cost of Goods Sold	1,937
Intangible Assets	0
Liabilities, Current	27,494
Liabilities, Non-Current	237
Other Assets	371
Other Compr. Net Income	0
Other Expenses	12,100
Other Liabilities	10,323
Other Net Income	0
Property and Equipment	12,173
Research and Development	71,379
Revenues	66
Selling, General and Administrative Expense	51,825

Output Variable	Value in 1000 USD
Assets	166,673
Liabilities	38,054
Expenses	137,241
Stockholders Equity	128,619
Net Income	-137,175
Comprehensive Net Income	-137,175
Economic Capital Ratio	-406%